FDA Considering Exclusivity Program As Antimicrobial Development Incentive

A drug exclusivity program is being considered by FDA as an incentive to encourage investment in antimicrobial product development, FDA Commissioner Henney, MD, indicated during a Senate Appropriations/Labor, HHS & Education subcommittee hearing Sept. 20.